A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

NCT01525394 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Solid Tumors
Lymphomas

Interventions

DRUG: Lenvatinib
DRUG: Moxifloxacin 400 mg
DRUG: Placebos (matched to 4 mg and 10 mg lenvatinib capsules).

Sponsor

Eisai Inc.